Evidence map›Paper›PMID 38385067›Full record

ArticleInternational journal of biological sciences2024

Hepatobiliary organoids differentiated from hiPSCs relieve cholestasis-induced liver fibrosis in nonhuman primates.

Hongmei Li, Jingyi Li, Ting Wang, Ke Sun, Guangrui Huang, Yulin Cao, Fenfang Wu, Anlong Xu

Open access · goldAbstract read
In one paragraph

Article in International journal of biological sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. [Clinical research progress of stem cell therapy for decompensated cirrhosis and liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  8. Organoids in cancer therapies: a comprehensive review.Frontiers in bioengineering and biotechnology · 2025
    Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hongmei LiSchool of Life Science, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Jingyi LiSchool of Life Science, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Ting WangSchool of Life Science, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Ke SunSchool of Life Science, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Guangrui HuangSchool of Life Science, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Yulin CaoBeizhong Jingyuan Biotechnology (Beijing) Limited, Beijing, People's Republic of China.
Fenfang WuShenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen 518116, People's Republic of China.
Anlong XuSchool of Life Science, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Beijing University of Chinese Medicine · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent need for novel therapies to treat end-stage liver disease due to the shortage of available organs. Although cell transplantation holds considerable promise, its availability is limited due to the low engrafted cell mass and lack of unifying cell transplantation strategies. Here, we optimally established human induced pluripotent stem cell-derived functional hepatobiliary organoids (HBOs) based on our previous research and transplanted them into a monkey model via liver subcapsular and submesenteric transplantation routes to assess their potential clinical application. Our study revealed that HBO transplantation could safely and effectively improve hepatoprotection effects by antiapoptotic and antifibrotic agents. In addition, we also discovered that while multiple HBO transplantation pathways may have a shared effector mechanism, their respective treatment approaches have distinct advantages. Transplantation of HBOs could promote the high expression of CTSV in hepatic sinusoid endothelial cells, which might halt the progression of hepatic sinusoidal capillarization and liver fibrosis. Liver subcapsular transplants had stronger pro-CTSV upregulation than HBO submesenteric transplants, which could be attributed to naturally high CTSV expression in HBOs. Interestingly, both transplantation routes of HBOs were targeted the injured liver and triggered a new pattern of ductular reaction to alleviate the degree of liver fibrosis by surrounding the area with CK19-positive labeled cells. These residing, homing and repairing effects might be related to the high expression of MMP family genes. By promoting a unique pattern of ductular reactions, submesenteric HBO transplantation has a more representative antifibrotic impact than liver subcapsular transplantation. Altogether, our data strongly imply that the treatment of severe liver diseases with liver subcapsular and submesenteric transplantation of HBOs may be clinically effective and safe. These findings provide new insight into HBOs for further experimental and clinical validation.

Indexed as

CholestasisInduced Pluripotent Stem CellsAnimalsEndothelial CellsHumansLiverLiver CirrhosisOrganoidsPrimatesHBOs induced from hiPSCsHepatoprotective effect and mechanismLiver subcapsular transplantationSafety and efficacySubmesenteric transplantation

Identifiers

PMID38385067
PMCPMC10878143
OpenAlexW4391581746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.